Gimbal Financial purchased a new stake in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 119,474 shares of the company’s stock, valued at approximately $6,478,000. ARK Genomic Revolution ETF comprises about 3.8% of Gimbal Financial’s holdings, making the stock its 9th largest holding.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Himension Capital Singapore PTE. LTD. purchased a new stake in ARK Genomic Revolution ETF in the 1st quarter worth about $2,250,000. Client First Investment Management LLC bought a new stake in ARK Genomic Revolution ETF in the 2nd quarter valued at about $2,579,000. Turner Financial Group Inc. purchased a new stake in ARK Genomic Revolution ETF during the second quarter valued at about $1,633,000. Group One Trading LLC lifted its holdings in ARK Genomic Revolution ETF by 168.3% during the first quarter. Group One Trading LLC now owns 45,861 shares of the company’s stock valued at $1,212,000 after purchasing an additional 28,765 shares during the last quarter. Finally, Moran Wealth Management LLC lifted its holdings in ARK Genomic Revolution ETF by 79.6% during the first quarter. Moran Wealth Management LLC now owns 49,204 shares of the company’s stock valued at $1,300,000 after purchasing an additional 21,811 shares during the last quarter.
ARK Genomic Revolution ETF Price Performance
BATS:ARKG traded up $0.66 on Monday, reaching $47.36. 2,613,432 shares of the company’s stock were exchanged, compared to its average volume of 3,373,501. ARK Genomic Revolution ETF has a 52 week low of $24.60 and a 52 week high of $58.83. The stock has a fifty day simple moving average of $48.87 and a 200-day simple moving average of $39.52.
About ARK Genomic Revolution ETF
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Further Reading
- Five stocks we like better than ARK Genomic Revolution ETF
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
- Insider Buying Is Rising at These 3 Regional Banks, But the Details Matter
- Illinois Tool Works Faces Headwinds—2 Alternatives Stand Out
- Luxury’s Middle Market Is Cracking—These 3 Stocks Could Win
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
